Hepatitis C virus (HCV)-related cirrhosis is the most common indication for liver transplantation (LT), with approximately one-third of all patients worldwide being transplanted for HCV-related complications. Virological recurrence of HCV after LT is universal and histological recurrence may appear in as many as 90% of patients. The natural history of HCV after LT is often accelerated and cirrhosis may develop in up to 20% of patients within five years of transplantation. Thus far, the treatment of recurrent HCV after LT using interferon alpha and ribavirin, alone or in combination, has yielded disappointing results. The combination therapy of standard interferon alpha 2b and ribavirin offers an end of treatment response (ETR) in 10% to 50% of patients but a sustained virological response (SVR) is more rarely observed. The pegylation of interferon leads to a longer half-life and increased efficacy; however, there has been limited experience with the combination of pegylated-interferon alpha 2b (PEG-IFN) and ribavirin in the treatment of recurrent HCV after LT. We report our experience using PEG-IFN and ribavirin in 13 LT recipients with recurrent HCV. Buy drugs with confidence – purchase antibiotics online to see how cheap your treatment can be.